Current neurology and neuroscience reports · 2026
Sleep in Children with Neurodevelopmental Disorders: From Diagnostic Labels to Phenotype-directed Care.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bruni Oliviero, Breda Maria, Mammarella Valeria, Polese Daniela, Mogavero Maria Paola, Lanza Giuseppe, Ferri Raffaele
Аннотация
PURPOSE OF REVIEW: Sleep disorders are highly prevalent in children with neurodevelopmental disorders (NDDs), but diagnostic labels alone provide limited guidance for assessment or treatment. This review summarizes recent advances and proposes a diagnosis-informed, phenotype-directed clinical framework.
RECENT FINDINGS: Recent studies reinforce the heterogeneity of sleep disturbance within and across autism, attention-deficit/hyperactivity disorder, intellectual disability, and genetic syndromes. Clinically relevant phenotypes include insomnia and circadian dysregulation, sleep-disordered breathing, sleep-related movement disorders, hypersomnolence, and parasomnias. Emerging research points to convergence among circadian, arousal, synaptic, sensory, and dopamine-iron pathways. Evidence for adapted behavioral interventions is growing. Melatonin has the strongest pharmacological evidence, particularly for insomnia in ASD and selected neurogenetic conditions, whereas evidence for other sedating agents and for many other NDD populations remains limited. Management should integrate diagnosis-informed risk recognition with phenotype-directed assessment. The neurodevelopmental diagnosis can identify syndrome-specific risks and surveillance needs, whereas the dominant sleep phenotype, contributing medical and environmental factors, and functional consequences should guide investigation and treatment. Better trials must include children with severe disability and rare NDDs and use developmentally appropriate, objective, and family-centered outcomes.
RECENT FINDINGS: Recent studies reinforce the heterogeneity of sleep disturbance within and across autism, attention-deficit/hyperactivity disorder, intellectual disability, and genetic syndromes. Clinically relevant phenotypes include insomnia and circadian dysregulation, sleep-disordered breathing, sleep-related movement disorders, hypersomnolence, and parasomnias. Emerging research points to convergence among circadian, arousal, synaptic, sensory, and dopamine-iron pathways. Evidence for adapted behavioral interventions is growing. Melatonin has the strongest pharmacological evidence, particularly for insomnia in ASD and selected neurogenetic conditions, whereas evidence for other sedating agents and for many other NDD populations remains limited. Management should integrate diagnosis-informed risk recognition with phenotype-directed assessment. The neurodevelopmental diagnosis can identify syndrome-specific risks and surveillance needs, whereas the dominant sleep phenotype, contributing medical and environmental factors, and functional consequences should guide investigation and treatment. Better trials must include children with severe disability and rare NDDs and use developmentally appropriate, objective, and family-centered outcomes.